Kenvue faces challenges with declining sales, cash flow risks, and high leverage. Read here for more analysis on KVUE stock.

Band-Aid and Tylenol maker Kenvue has fired its CEO Thibaut Mongon, the consumer health company said on Monday, laying what ...

Two years ago, when Johnson & Johnson announced it was spinning off its consumer brands including Tylenol, Band-Aid, Motrin, ...

American consumer health company Kenvue's Board of Directors announced new actions to unlock shareholder value and an interim ...

Kenvue Inc ousted its chief executive and announced a strategic review on Monday. Jefferies says KVUE shares could rally to ...

The Johnson & Johnson spinoff that makes Tylenol and Benadryl, said Chief Executive Thibaut Mongon has departed and that the ...

Echoing this, short-term traders are also sporting a call-bias. This is per the security's Schaeffer's put/call open interest ...

Crypto-sensitive stocks rose, as [bitcoin prices rallied to another high]( ...

Kenvue stock approaches a Golden Cross, signaling bullish momentum with the stock up 10% over the past month. Legal win over Tylenol gelcaps boosts Kenvue's momentum, as strong brand power fuels ...

Why It Matters: Kenvue’s stock price has remained relatively unchanged this year, in contrast to the S&P 500 index’s 23% increase.The company’s biggest competitors include Haleon, the parent ...

Kenvue Non-GAAP EPS of $1.29 beats by $1.01, revenue of $3.7B misses by $90M Kenvue gains as ruling in Tylenol case likely collapses plaintiffs case - analyst Recommended For You ...

Kenvue's CEO and board member Thibaut Mongon has stepped down, it said on Monday, in the second big executive change at the ...